Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new?

 

Launch of accredited Type 1 Childhood Diabetes CME

A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.

Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC). 

 

Anti-Infectives Knowledge Network (AIKN) CDI Updates

Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.

This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.

January 2015 FDX/15/0003/EU

 

Bedwetting CME

This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.

 

Accredited Obesity CME

The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.

 

Type 2 Diabetes accredited CME

‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:

  • A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
  • Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
  • Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
     

Latest News

Combination of daclatasvir + sofosbuvir positive in ALLY-2 trial for co-infected HIV and hepatitis C patients- BMS

28-Feb-2015

BMS announced results from ALLY-2 , a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient ...

FDA approves Liletta for contraception-Actavis/Medicines360

28-Feb-2015

Actavis and Medicines360 have announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the FDA for use by women to prevent pregnancy for up to three years. Liletta is placed in the uterus by a healthcare professional and ...

EU approves Eylea for Visual Impairment RVO-Regeneron Pharma

28-Feb-2015

Regeneron Pharmaceuticals has announced that Eylea (aflibercept) injection has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo). The new indication ...

CHMP recommends Zycadia (ceritinib)to treat ALK + NSCLC- Novartis

28-Feb-2015

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced ...

Positive results for Alprolix in Kids B-LONG study treatment for haemophilia B- SOBI+ Biogen

28-Feb-2015

Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase III clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion ...

Sorin Group to merge with Cyberonics Inc.

27-Feb-2015

Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a medical device company with core expertise in neuromodulation, announced their merger plan to create a new global leader in ...

FDA approves Toujeo (insulin glargine [rDNA origin]) for treatment of Type 1 and Type 2 Diabetes-Sanofi

27-Feb-2015

Sanofi announced that the FDA approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be ...

Recent Updates

Drugs

Clinical Guidelines

Guidelines on Prostate Cancer

Early and locally advanced breast cancer: Diagnosis and treatment

Medical Journals

How growth due to infant nutrition influences obesity and later disease risk

A comparison of obesity related adipokine concentrations in knee and shoulder osteoarthritis patients

The implications of obesity on pregnancy outcome

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

epgonline.org Social